A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate.

Abstract

Atypical chronic myelogenous leukemia (aCML) is a myelodysplastic/myeloproliferative disorder that usually occurs in older adults. Here we report a pediatric patient with aCML and a t(5;12)(q33;p13) with a corresponding fusion gene ETV6-PDGFRB. Because the PDGFRB tyrosine kinase is one of the known targets of tyrosine kinase inhibitors, this patient achieved cytogenetic and molecular remission with treatment with imatinib mesylate (formerly STI571; now Gleevec in the United States and Glivec in Europe). This case illustrates one of many myelodysplastic/myeloproliferative disorders that can be treated with this particular tyrosine kinase inhibitor.

• Authors: Brenda Wittman, John Horan, Joanna Baxter, John Goldberg, Raymond Felgar, Erin Baylor, Bean Cromwell, Nicholas Cross, John M Bennett
• Journal: Leukemia research (Leuk Res) Vol. 28 Suppl 1 Pg. S65-9 (May 2004) ISSN: 0145-2126 [Print] England
• PMID: 15036944 (Publication Type: Case Reports, Journal Article)

Chemical References

• Benzamides
• ETV6-PDGFRB fusion protein, human
• Oncogene Proteins, Fusion
• Piperazines
• Pyrimidines
• Imatinib Mesylate

Topics

• Benzamides
• Child, Preschool
• Chromosomes, Human, Pair 12
• Chromosomes, Human, Pair 5
• Female
• Humans
• Imatinib Mesylate
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy, genetics, pathology)
• Oncogene Proteins, Fusion (antagonists & inhibitors)
• Piperazines (therapeutic use)
• Pyrimidines (therapeutic use)
• Remission Induction
• Translocation, Genetic